OncoMatch/Clinical Trials/NCT07218926
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Is NCT07218926 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including IDRX-42 and Sunitinib for gastrointestinal neoplasms.
Treatment: IDRX-42 · Sunitinib — The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Prior therapy
Must have received: imatinib (imatinib) — first-line treatment of unresectable/metastatic disease
Documented disease progression on or intolerance to imatinib administered for first-line treatment of unresectable/metastatic disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Boston, Massachusetts
- GSK Investigational Site · Omaha, Nebraska
- GSK Investigational Site · New York, New York
- GSK Investigational Site · Philadelphia, Pennsylvania
- GSK Investigational Site · Knoxville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify